GARDP and the Global Antimicrobial Resistance Innovation Fund, part of the UK Department of Health and Social Care, are pleased to announce £1 million of funding to support GARDP’s efforts to develop treatments for the drug-resistant infections that pose the greatest threat to global health.
GARDP is very pleased to announce renewed funding by the South African Medical Research Council (SAMRC) to tackle drug-resistant infections. The SAMRC is providing an additional 3.9 million South African rand (ZAR) to support GARDP’s activities in developing new and improved antibiotic treatments for drug-resistant infections that pose the greatest threat to health.
GARDP and the Indian Council of Medical Research have signed a Memorandum of Understanding to explore joint opportunities to tackle antibiotic resistance in India and globally.
GARDP and the French Ministry for Europe and Foreign Affairs have signed a Declaration of Intent to explore opportunities to collaborate on and strengthen activities to tackle antibiotic resistance.
The UK government has announced an additional £1.5 million of funding to develop a new treatment for gonorrhoea. This investment, on top of £3.5 million committed in 2019, will support GARDP in the development and availability of zoliflodacin, a novel antibiotic, which is currently being assessed as part of a global phase 3 trial for safety and effectiveness as a treatment for gonorrhoea.
GARDP and BSAC sign MOU to establish framework for collaborating on education, policy and advocacy activities.
GENEVA, SWITZERLAND– The Global Antibiotic Research and Development Partnership (GARDP), Dr. Reddy’s Laboratories Ltd (Dr. Reddy’s) and Aurigene Pharmaceutical Services Limited (APSL) have signed a … GARDP, Dr. Reddy’s and Aurigene Pharmaceutical Services Limited sign MOU for antibiotic access through collaborative model
The Global Antibiotic Research and Development Partnership (GARDP), the Foundation for Innovative New Diagnostics (FIND), and the World Health Organization (WHO) have signed a memorandum of understanding to explore joint initiatives that could improve the sustainable access to antibiotics and protect them against the emergence of antimicrobial resistance (AMR), with an initial focus on sexually transmitted infections (STIs).
GARDP welcomes Germany’s increased commitment to preventing and combatting global pandemics through funding to accelerate the development of new treatments for drug-resistant serious bacterial infections in hospitalized people.
GENEVA – The Global Antibiotic Research and Development Partnership (GARDP) has announced a collaboration with Bugworks Research Inc (“Bugworks”), an Indo-USA-Australian biopharmaceutical group developing new … GARDP and Bugworks Research Inc sign MOU to explore antibiotic development to tackle serious bacterial infections in high-burden countries